Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Mizuho Maintains Buy on Insmed, Raises Price Target to $82

Author: Benzinga Newsdesk | June 07, 2024 07:33am
Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $36 to $82.

Posted In: INSM